Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with multiple myeloma and still have signs of the disease that can be measured.
- People who use contraception in line with the rules that apply in their country for those taking part in clinical studies.
For the first part of the trial (Dose Escalation – Part A):
- People who have already tried at least 3 different myeloma treatments, and whose myeloma has come back, stopped responding to those treatments, or who could not tolerate them.
- Previous treatment targeting GPRC5D or BCMA (two specific proteins on myeloma cells) is permitted in this part (confirm with trial site).
For the second part of the trial (Dose Optimisation – Part B):
- People who have already tried at least 3 different myeloma treatments, and whose myeloma has come back, stopped responding, or who could not tolerate at least four specific types of treatment: an immunomodulator, a proteasome inhibitor, an anti-CD38 antibody, and a BCMA-targeting treatment.
- Previous treatment targeting GPRC5D is not permitted in this part (confirm with trial site).
Who may not be able to join:
- People whose general health and ability to carry out daily activities falls below a certain level, as measured by a standard medical scoring system (confirm with trial site).
- People with certain related blood or nerve conditions, including AL amyloidosis, POEMS syndrome, active plasma cell leukaemia, or multiple myeloma that has spread to the brain or nervous system.
- People who have received any myeloma treatment within 14 days before the start of the trial treatment.
- People who have received a specific type of therapy that engages natural killer cells (a part of the immune system) within 90 days before the start of the trial treatment.
- People whose organs (such as kidneys or liver) or bone marrow are not functioning well enough to meet the trial's requirements.
- People with other serious illnesses occurring at the same time as their myeloma.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 800-633-1610
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Dose Limiting Toxicities (DLTs)- Dose escalation (Part A); Overall response rate (ORR) - Dose optimization (Part B)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.